Compare Bank of Nova Scotia (BNS) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Cronos Group Inc — how do they compare? Bank of Nova Scotia trades at $89.04 (market cap $108.17B), while Cronos Group Inc trades at $2.74 (market cap $1.02B). The key difference: Bank of Nova Scotia is far larger — about 106× Cronos Group Inc's market cap, and Bank of Nova Scotia pays a 3.61% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| BNS | CRON | |
|---|---|---|
Market Cap | $108.17B | $1.02B |
Sector | Financials | Health |
52-Week High | $88.99 | $3.27 |
52-Week Low | $54.50 | $1.95 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $203.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.00, up 0.47% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 earnings beating expectations, revenue growth to $37.1B, and a healthy 24.86% net income margin. Recent acquisition of MapleMark Bank supports strategic growth initiatives while the dividend increase to $1.14 signals management confidence.
BNS presents a compelling investment case with consistent earnings beats, attractive dividend yield, and strategic expansion. However, elevated valuation multiples and macroeconomic sensitivity in the banking sector warrant caution. Analyst consensus remains positive with 53% buy ratings, though the stock trades near resistance levels requiring careful entry timing.
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
